Rational design of mixed nanomicelle eye drops with structural integrity investigation

Sun, Leilei; Zhang, Meng; Shi, Yu; Fang, Lei; Cao, Feng

doi:10.1016/j.actbio.2022.01.014

Cited by 16 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DurystaTM is a bimatoprost implant that will receive FDA approval in the year 2020. It is made up of poly-lactic acid and poly-lactic-co-glycolic polymers, which are similar to biodegradable sutures that are utilised in clinical settings [99]. It is meant to deliver a non-pulsatile release of 10 micrograms of bimatoprost and is implanted intracamerally before administration.…”

Section: Preclinical Studiesmentioning

confidence: 99%

Recent Advancement in Ocular Drug Delivery System: A Systematic Review

Mittal,

Amle,

Kumar

et al. 2023

J. Res. Appl. Sci. Biotechnol.

View full text Add to dashboard Cite

Recent scientific and technological advancements have made ophthalmology a top priority for the study of therapeutic products, including the creation, preclinical testing, and clinical evaluation of novel medications, medical devices, and drug-medical device combinations. In order to decrease metabolism and elimination and increase residence time in ocular tissues and compartments, sustained-release drug delivery systems such as liposomes, micelles, nano-emulsions, nanoparticles with colloidal structures, and intraocular implants have been developed. Research is also being conducted in the area of cutting-edge medicines, including those based on gene or cell systems, both of which are considered high-risk products because to their intricate structures. Regarding the definition of drug (medicinal product) and recent changes in regulation, this article reviews recent advancements in ophthalmic drug, gene, and cellular delivery systems and related goods as well as breakthroughs in advanced therapeutic medicinal Products.

show abstract

Section: Preclinical Studiesmentioning

confidence: 99%

Recent Advancement in Ocular Drug Delivery System: A Systematic Review

Mittal,

Amle,

Kumar

et al. 2023

J. Res. Appl. Sci. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Lysosomal entrapment is a major obstacle to be tackled in the drug delivery process, and efficient lysosomal escape is a major capability required for intracellular drug delivery vehicles [29]. Since laser irradiation of THPP could generate singlet oxygen, this course of action can destroy lysosomes and promote nanoparticle escape.…”

Section: Lysosomal Escape Of Tpg Npsmentioning

confidence: 99%

Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy

Zhou

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Pancreatic carcinoma is an aggressive subtype of cancer with poor prognosis, known for its refractory nature. To address this challenge, we have established a stable nanoplatform that combines chemotherapy with photodynamic therapy (PDT) to achieve better curative efficacy. First, we designed and synthesized a disulfide-bonded paclitaxel (PTX)-based prodrug, which was further mixed with gemcitabine (GEM) and photosensitizer THPP in an optimized ratio. Subsequently, the mixture was added dropwise into amphiphilic polymer DSPE-PEG water solution to form micelles composed of DSPE-PEG nanoparticles (TPG NPs). The TPG NPs were around 135 nm, and showed great ability of DTT stimulated release of PTX and GEM. Moreover, the TPG NPs can be efficiently uptaken by pancreatic cancer PANC-1 cells and effectively kill them, especially when combined with 650 nm laser irradiation. Finally, the TPG NPs have shown enhanced long-term circulation ability and also exhibited efficient anti-tumor activity in combination with 650 nm laser irradiation in a pancreatic cancer mouse model. In summary, the designed TPG NPs possesses great potential for co-delivery of paclitaxel prodrug, GEM and THPP, which enables combined chemo-photodynamic therapy for cancer treatment. In addition, the stimulated release of PTX prodrug and GEM also allows for better targeting of tumor cells and the increased therapeutic effect against cancer cells. Overall, the TPG NPs can serve as a good candidate for pancreatic cancer treatment.

show abstract

“…Various nanoscale drug delivery systems, such as liposomes [ 22 , 23 ], niosomes [ 24 , 25 ], solid lipid/polymeric nanoparticles [ 26 , 27 , 28 , 29 ], nanostructured lipid carriers [ 30 , 31 ], nanomicelles [ 32 , 33 ], microemulsions [ 34 , 35 ], and dendrimers [ 36 ], have been successfully developed for ocular delivery purposes, and have been reported to achieve enhanced bioavailability, sustained and controlled drug release, and a reduction in the number of applications, as well as side effects. SLNs and NLCs raise great interest due to their excellent biocompatibility and tolerability, tunable physiochemical characteristics, and scaling-up capabilities [ 37 , 38 , 39 ].…”

Section: Introductionmentioning

confidence: 99%

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Gugleva

Andonova

2023

Pharmaceuticals

View full text Add to dashboard Cite

Sufficient ocular bioavailability is often considered a challenge by the researchers, due to the complex structure of the eye and its protective physiological mechanisms. In addition, the low viscosity of the eye drops and the resulting short ocular residence time further contribute to the observed low drug concentration at the target site. Therefore, various drug delivery platforms are being developed to enhance ocular bioavailability, provide controlled and sustained drug release, reduce the number of applications, and maximize therapy outcomes. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) exhibit all these benefits, in addition to being biocompatible, biodegradable, and susceptible to sterilization and scale-up. Furthermore, their successive surface modification contributes to prolonged ocular residence time (by adding cationic compounds), enhanced penetration, and improved performance. The review highlights the salient characteristics of SLNs and NLCs concerning ocular drug delivery, and updates the research progress in this area.

show abstract

Rational design of mixed nanomicelle eye drops with structural integrity investigation

Cited by 16 publications

References 38 publications

Recent Advancement in Ocular Drug Delivery System: A Systematic Review

Recent Advancement in Ocular Drug Delivery System: A Systematic Review

Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment via Chemo-Photodynamic Combination Therapy

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Contact Info

Product

Resources

About